fbpx Skip to content

Welcome Partners!

Find Your Way Forward with the AdaptDx Pro

The AdaptDx Pro® guided by Theia™ headset dark adaptometer helps ECPs measure dark adaptation speed, the earliest biomarker for age-related macular degeneration (AMD). Discover what optometrists love about this easy-to-use, portable device as they utilize dark adaptation testing to level up their practice.

Join the AMD Revolution


Practical Implementation of Dark Adaptation in Optometric Practice

E-Book: Practical Implementation of Dark Adaptation in Optometric Practice

Going beyond explaining why dark adaptation is so important in optometric practice. Having already established the reasons why functional testing is essential, this year’s report outlines the practical strategies for how to make routine testing a reality in your own eye care practice.


Fight AMD For Only $99/Month

For a limited time, you can leverage the power of the AdaptDx Pro to fight AMD in your practice for only $99 a month for 6 months with our subscription plan, available to U.S. eye care providers only.*

Take on one of eye care’s biggest opportunities to impact patients’ lives and practice revenue with a subscription plan for the AdaptDx Pro, the dark adaptometer headset with built-in AI technician, Theia. You can focus on your patients and their medical needs while creating opportunities to boost revenue, thanks to your low monthly payment.

Contact us today to learn more about the clinical and financial benefits of the AdaptDx Pro.

*Offers applies to a 42-month premium subscription plan. Ask your Regional Sales Executive for full details. This offer is valid for eye care professionals in the US only.


Customer Success Stories

Our collection of customer success stories offers a look at some of the benefits of integrating dark adaptation testing into your patient care arsenal. Learn how your fellow eye care professionals utilize AdaptDx® technology as they work towards improved outcomes for their AMD patients as well as their practice.


Read our Featured Blog

5 Tips for Recommending Smoking Cessation Programs

Dr. Timothy Earley shares tips on how to talk to patients about smoking cessation, the biggest modifiable risk factor for AMD, and how to motivate them to quit.

Macular degeneration

Tour our Virtual Exhibit

Our interactive Virtual Exhibit allows you to meet the newest member of our team – Theia, the on-board technician for the AdaptDx Pro headset dark adaptometer. Theia will welcome you to the booth as you learn how tackling AMD can benefit your practice.

Explore the exhibit at your leisure – without any sales pressure – and see this amazing technology for yourself. When you are ready to learn more, just enter your ZIP Code into the laptop in the booth to find your Regional Sales Executive.


Find Your Way Forward

Early detection and treatment of AMD can help you combat the leading cause of adult blindness in the US while doing the right thing for your patients and your practice. Here’s how:

1. Put Patient Care First

Accept the challenge to tackle AMD, one of eye care’s biggest opportunities to impact patients’ lives.

2. Create Efficiency & Focus on Hygiene

The AdaptDx Pro is guided by Theia, an onboard technician who increases consistency in each patient’s testing experience, freeing up your techs to attend to other tasks.

3. Drive Medical Revenue

Patient discretionary spending may be reduced, even for months – making medical revenue more vital than ever. Dark adaptation testing is a reimbursable service, using CPT 92284, that can dramatically increase revenue for your practice.

4. Create Revenue from Current Patients

The AdaptDx Pro leverages patients already in the practice, allowing you to generate revenue as quickly and easily as possible, without the need to market and acquire a new audience.

5. Increase Cash Reserves

Eye care professionals are dealing with reduced cash flow, making it difficult to invest in new technology. Our new subscription model allows you to start earning revenue with minimal up-front investment.


Impaired Dark Adaptation: The Earliest Biomarker of AMD (video)

Before drusen are visible, an invisible layer of cholesterol builds up between the pigmented layer of the retina (RPE) and the elastic layer of Bruch’s membrane. These cholesterol deposits — basal laminar (BLamD) and basal linear (BLinD) — cause oxidative stress and inflammation, hindering nutrient transportation to photoreceptor cells. As photoreceptor cells die, it becomes harder for the eyes to adjust to the darkness, and night vision declines. This dark adaptation impairment is the first sign of AMD.

The cholesterol deposits grow over time. Where they become sufficiently thickened, the lesion becomes clinically detectable as a druse. The first visible druse caused by AMD is just the tip of the iceberg of these lesions.

Research has shown that impaired dark adaptation function can be detected at least three years before drusen are clinically evident, allowing for earlier diagnosis, treatment, and monitoring of AMD.

Partner with MacuLogix

Implementation Expertise

Each AdaptDx Pro® purchase is supported by our AMD Excellence Program®️ to help you achieve your patient care and practice revenue goals.

Contact Our Sales Team

As the AMD Experts®, our sales team is here to answer your questions about the clinical and financial benefits of the AdaptDx Pro.